MSToronto2026 – 10th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026
Wednesday, October 21. 16:30 – 18:30
- POSTER P116: BTK Inhibitors Modulate Remyelination in Multiple Sclerosis
- POSTER 618: Evaluating Ofatumumab Excretion in Breastmilk of Women Living With Relapsing Multiple Sclerosis: Interim Results of the Phase 4 KATHAROS Study
- POSTER P840: Real-World Effectiveness and Safety of Satralizumab in AQP4-IgG+ NMOSD: A Multicenter Latin American Cohort Study (SATRA-LATAM)
- POSTER P1030: A Nordic Observational Study on the Risk of Multiple Sclerosis Associated with Infectious Mononucleosis Caused by Epstein-Barr Virus: A Fixed-Effects Meta-Analysis of Register Data from Denmark, Sweden, and Finland
- POSTER P1685: EBV Reactivation and Neuroaxonal Injury in Multiple Sclerosis Relapses
- POSTER P1490: Safety and Tolerability of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3.5-Year Results From the Phase 2 Open-label Extension
- POSTER P2236: Impact of Vaccination Timing on Hepatitis B Serological Response in Patients Treated with Anti-CD20 Therapies
- POSTER P2053: Comparative Efficacy and Safety of Tocilizumab versus Ofatumumab in MOG-Antibody Associated Disease: A Longitudinal Real-World Cohort Study
Canadian co-authored studies
- POSTER P169: Value of annual MRI monitoring in ocrelizumab treatment: a number needed to scan analysis
- POSTER P421: Optimizing the Management of AQP4-IgG+ NMOSD: a Canadian Consensus
- POSTER P463: Prevalence of Cardiovascular Comorbidities and Their Association on Disease Outcomes in Patients with Seropositive NMOSD and MOGAD in a Canadian Cohort.
- POSTER P748: Pregnancy and Infant Outcomes in Women With Relapsing Multiple Sclerosis Following Exposure to Ofatumumab: Latest Evidence From the PRIM Study. See also P2105.
- POSTER P927: Long-Term Impact of First-Line Ocrelizumab Treatment in Early-Stage Relapsing-Remitting Multiple Sclerosis: Results From the 6-Year Phase III ENSEMBLE-LIBERTO Study